Eric Souied Joins SeaBeLife
French biotechnology company, SeaBeLife, welcomes AMD specialist to its scientific committee
Clinical Scorecard: Eric Souied Joins SeaBeLife
At a Glance
Category Detail
Condition Age-Related Macular Degeneration (AMD) Key Mechanisms Inhibition of necroptosis and ferroptosis Target Population Individuals with geographic atrophy (GA) associated with AMD Care Setting Ophthalmology clinics and research settings
Key Highlights
Professor Eric Souied appointed to SeaBeLife's scientific committee Focus on dual-pathway strategy targeting retinal degeneration SBL03 shows preclinical efficacy in geographic atrophy GA affects an estimated eight million people worldwide Limited treatment options available in Europe Guideline-Based Recommendations
Diagnosis
Identify genetic polymorphisms associated with AMD Assess for geographic atrophy in early-stage disease Management
Implement disease-modifying approaches targeting necroptosis and ferroptosis Monitoring & Follow-up
Regular assessments of retinal health and progression of GA Risks
Progressive loss of retinal pigment epithelium and photoreceptors Patient & Prescribing Data
Patients with geographic atrophy due to AMD
Focus on addressing underlying drivers of degeneration
Clinical Best Practices
Utilize a mechanistic approach to understand retinal degeneration Incorporate lipid metabolism and oxidative stress in treatment strategies Engage in regulatory strategy and trial design for new therapies Related Resources & Content
